



5-9-05

PATENT  
*Ifw  
JF*

OCKET NO.: AM101201 US/WYNC-0325

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## In Re Application of:

Deborah A. Evrard, et al.

Confirmation No.: 4846

Application No.: 10/659,537

Group Art Unit: 1624

Filing Date: September 10, 2003

Examiner: Emily B. Bernhardt

For: ANTIDPRESSANT ARYLPiperazine DERIVATIVES OF  
HETEROCYCLE-FUSED BENZODIOXANSEXPRESS MAIL LABEL NO: EV 614725845 US  
DATE OF DEPOSIT: May 6, 2005

EV 614725845 US

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

Certification in Accordance with § 1.97(e) is attached; or

The fee of \$180.00 as set forth in § 1.17(p) is attached.

In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

Copies of reference numbers 23-29 listed on the attached Form PTO-1449 are enclosed herewith.

Copies of reference numbers on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

Copies of references are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

There are no listed references which are not in the English language.

**DOCKET NO.: AM101201 US/WYNC-0325- 3 -**

**PATENT**

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: May 6, 2005

  
\_\_\_\_\_  
Wendy A. Choi  
Registration No. 36,697

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

© 2005 WW



Sheet 1 of 1

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. AM101201 US/ WYNC-0325	Application No. 10/659,537
		Applicant Deborah A. Evrard, et al.	
		Filing Date September 10, 2003	Group 1624
		Confirmation No. 4846	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	23	Bundgaard, H. (ed.), <i>Design of Prodrugs</i> , Elsevier (1985), Ch. 1 (pp. 1-92), Ch. 4 (pp. 157-176), Ch. 5 (pp. 177-198), and Ch. 6 (pp. 199-241).	
	24	Bundgaard, H. et al., "Glycolamide Esters as Biodegradable Prodrugs of Carboxylic Acid Agents: Synthesis, Stability, Bioconversion, and Physicochemical Properties," <i>J. of Pharmaceutical Sciences</i> , April 1988, 77(4):285-298	
	25	Eliel, E. L., <i>Stereochemistry of Carbon Compounds</i> , McGraw Hill, NY (1962) Ch. 4, pp. 46-87	
	26	Higuchi and Stella (eds.), <i>Prodrugs as Novel Drug Delivery Systems</i> , American Chemical Society (1975), pp. 1-115 and 196-223	
	27	Jacques, J. et al., <i>Enantiomers, Racemates and Resolutions</i> , Wiley Interscience, NY (1981) pp. 251-434	
	28	<i>Remington's Pharmaceutical Sciences</i> , 17 <sup>th</sup> Ed., Gennaro, A. R. (Ed.), Mack Publishing Company, Easton, PA (1985) pp. 1409-1677	
	29	Widder, et al. (ed.), <i>Methods in Enzymology</i> , Vol. 112, Academic Press (1985), pp. 309-396	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	